×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CLDX – celldex therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CLDX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/20
09:00 am
cldx
Celldex Therapeutics (CLDX) was upgraded by Barclays PLC from "underweight" to "overweight". They now have a $45.00 price target on the stock.
Medium
Report
Celldex Therapeutics (CLDX) was upgraded by Barclays PLC from "underweight" to "overweight". They now have a $45.00 price target on the stock.
4/13
04:01 pm
cldx
Celldex to Present at Upcoming Investor Conference
Low
Report
Celldex to Present at Upcoming Investor Conference
4/6
10:53 am
cldx
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Low
Report
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
4/2
07:49 am
cldx
Is Celldex's US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX? [Yahoo! Finance]
Medium
Report
Is Celldex's US$300 Million Follow-On To Fund Barzolvolimab Altering The Investment Case For CLDX? [Yahoo! Finance]
4/2
02:10 am
cldx
Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch [Seeking Alpha]
Low
Report
Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch [Seeking Alpha]
4/1
10:40 pm
cldx
Celldex Announces Pricing of $300 Million Public Offering of Common Stock [Yahoo! Finance]
Low
Report
Celldex Announces Pricing of $300 Million Public Offering of Common Stock [Yahoo! Finance]
4/1
09:48 pm
cldx
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
Low
Report
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
4/1
04:01 pm
cldx
Celldex Announces Proposed Public Offering of Common Stock
Low
Report
Celldex Announces Proposed Public Offering of Common Stock
Date
Time
Symbol
Company Name
Action
%Chg
2/25/2026
04:01 pm
CLDX
celldex therapeutics, inc.
MISS
Report
-0.6%
celldex therapeutics, inc.
11/10/2025
04:01 pm
CLDX
celldex therapeutics, inc.
MISS
Report
7.5%
celldex therapeutics, inc.
5/8/2025
04:01 pm
CLDX
celldex therapeutics, inc.
MISS
Report
-6.1%
celldex therapeutics, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/2
05:15 pm
cldx
Form 424B5 Celldex Therapeutics,
Low
Report
Form 424B5 Celldex Therapeutics,
4/2
08:08 am
cldx
Form 8-K Celldex Therapeutics, For: Apr 01
Medium
Report
Form 8-K Celldex Therapeutics, For: Apr 01
4/1
04:08 pm
cldx
Form 424B5 Celldex Therapeutics,
Low
Report
Form 424B5 Celldex Therapeutics,
3/26
05:16 pm
cldx
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: VANGUARD GROUP INC
Medium
Report
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: VANGUARD GROUP INC
3/10
06:42 pm
cldx
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Point72 Asset Management, L.P.
Low
Report
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Point72 Asset Management, L.P.
2/25
04:08 pm
cldx
Form 10-K Celldex Therapeutics, For: Dec 31
Low
Report
Form 10-K Celldex Therapeutics, For: Dec 31
2/25
04:01 pm
cldx
Form 8-K Celldex Therapeutics, For: Feb 25
Low
Report
Form 8-K Celldex Therapeutics, For: Feb 25
2/10
11:22 am
cldx
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP
Low
Report
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: WELLINGTON MANAGEMENT GROUP LLP
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
2/20
Celldex Therapeutics, Inc. (NASDAQ: CLDX) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
30.1%
4/28 Form DEF 14A Celldex Therapeutics, For: Jun 18 9.6%
3/26 Q4/2019 12/31/2019 EPS -0.640 ZacksConsensus N/A ActVsEst N/A - N/A 3.4%
8/7 Q2/2019 6/30/2019 EPS -0.840 ZacksConsensus -1.170 ActVsEst 0.330 - Beat 2.3%
6/21 Form S-8 Celldex Therapeutics, 2.0%
10/2 Celldex Therapeutics Announces Upcoming Data Presentations 1.9%
10/9 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 1.4%
12/23 Is Celldex Therapeutics, Inc. (CLDX) A Good Stock To Buy? [Yahoo! Finance News] 1.3%
2/12 Form SC 13G Celldex Therapeutics, Filed by: RENAISSANCE TECHNOLOGIES LLC 0.4%
5/24 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 0.4%
4/28 Form DEF 14A Celldex Therapeutics, For: Jun 18 9.6%
3/26 Q4/2019 12/31/2019 EPS -0.640 ZacksConsensus N/A ActVsEst N/A - N/A 3.4%
8/7 Q2/2019 6/30/2019 EPS -0.840 ZacksConsensus -1.170 ActVsEst 0.330 - Beat 2.3%
6/21 Form S-8 Celldex Therapeutics, 2.0%
10/2 Celldex Therapeutics Announces Upcoming Data Presentations 1.9%
10/9 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.25 price target on the stock. 1.4%
12/23 Is Celldex Therapeutics, Inc. (CLDX) A Good Stock To Buy? [Yahoo! Finance News] 1.3%
2/12 Form SC 13G Celldex Therapeutics, Filed by: RENAISSANCE TECHNOLOGIES LLC 0.4%
5/24 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 0.4%
TOP News Decliners
3/27
Form 424B5 Celldex Therapeutics,
-12.3%
6/1 Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma -9.6%
11/8 CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study -9.2%
12/6 Form S-3 Celldex Therapeutics, -9.1%
11/12 Q3/2019 9/30/2019 EPS -0.750 ZacksConsensus -0.840 ActVsEst 0.090 - Beat -7.3%
11/18 Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159 -5.9%
3/3 Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program -4.6%
5/7 Q1/2019 3/31/2019 EPS -1.400 ZacksConsensus -1.140 ActVsEst (0.260) - Miss -3.6%
5/8 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was given a new $19.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -2.8%
7/31 Celldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call -2.8%
6/1 Celldex Announces Data from CDX-3379 Clinical Program Presented at ASCO 2019; Promising Biomarker Strategy Identified for Head and Neck Squamous Cell Carcinoma -9.6%
11/8 CDX-1140 Demonstrates Clinical and Biological Activity in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Study -9.2%
12/6 Form S-3 Celldex Therapeutics, -9.1%
11/12 Q3/2019 9/30/2019 EPS -0.750 ZacksConsensus -0.840 ActVsEst 0.090 - Beat -7.3%
11/18 Celldex Initiates Phase 1 Study of KIT Inhibitor CDX-0159 -5.9%
3/3 Celldex Therapeutics Announces $1.7 Million Milestone Payment from Rockefeller University Related to Collaboration on HIV Antibody Program -4.6%
5/7 Q1/2019 3/31/2019 EPS -1.400 ZacksConsensus -1.140 ActVsEst (0.260) - Miss -3.6%
5/8 Celldex Therapeutics, Inc. (NASDAQ: CLDX) was given a new $19.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. -2.8%
7/31 Celldex to Report Second Quarter 2019 Financial Results and Host Corporate Update Call -2.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: